Add like
Add dislike
Add to saved papers

Bedbugs: a primer for the health-system pharmacist.

PURPOSE: The history and life cycle of bedbugs, the identification and supportive treatment of bedbug bites, and the eradication and prevention of bedbug infestations are reviewed.

SUMMARY: Cimex lectularius, known commonly as the bedbug, is a growing problem in the United States. While the bedbug population declined between the 1950s and the late 20th century, recent increases in international travel and immigration, the banning of dichlorodiphenyltrichloroethane, and insecticide resistance have caused a resurgence of bedbug infestations. Infestations can be identified based on clinical presentation and situational indicators such as housing location and the presence of bedbug fecal smears and nests. Chronic infestation can lead to nervousness, anxiety, and insomnia arising from the inability to identify and eradicate the problem. Scratching at the bite site can lead to a secondary bacterial infection. Because bedbugs continue to bite until the infestation is eradicated, treatment is not accomplished by one strategy alone. A team effort by different health care professionals is necessary. Because bedbugs are hardy insects, eradication can be a daunting task. Proper eradication plans should be in place at all health care facilities, and bedbug infestations should be reported to the state public health department to support the tracking and management of bedbugs.

CONCLUSION: Bedbug infestations are prevalent in locations with high occupant turnover, including hospitals and health systems. Bedbug bites can cause secondary infections and lead to discomfort and anxiety in affected individuals. Pharmacists should work with other health care providers to provide affected patients with supportive treatment and ensure appropriate eradication of the infestation.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app